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ABSTRACT
Valsartan is one of the antihypertensive agents under angiotensin II receptor
blocker (ARB) group that commonly used in treating hypertensive patient
with underlying heart failure, chronic kidney disease and angiotensin
converting enzyme inhibitor (ACE-i) drug’s intolerance. We report a case of
Valsartan induced exanthematous macular skin lesions. This case illustrates
a rare adverse cutaneous effect of Valsartan with skin manifestation that
mimicking other common skin diseases. Clinicians should consider Valsartan
as one of the triggering factors for exanthematous skin manifestation.
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INTRODUCTION
Valsartan is one of the common angiotensin II receptor
blocker (ARB) that typically used in the treatment of
hypertension, heart failure and chronic kidney disease
(CKD). In certain circumstances, it is used as an alternate
in patients who are intolerant to angiotensin converting
enzyme inhibitors (ACE-i) 1. It selectively blocks
angiotensin 1 receptor and hence it prevents the action of
angiotensin II, a potent vasoconstrictor1. In the limited
number of case report, there is a rare event of Valsartan-
related cutaneous side effects manifestation2,3,4. This case
report highlighted the rare skin manifestation related to
Valsartan prescribed to control hypertension.
CASE REPORT
A 45-year-old man with underlying chronic hypertension
for one year and on daily Exforge® (Amlodipine 10mg
and Valsartan 160mg) presented with gradual onset of
generalised bilateral hyperpigmented skin lesions from
both feet upwards in the past eight months. He visited
many clinicians for his skin lesions and was treated as an
eczema, yet the lesions were getting worse. He also was
prescribed with oral antifungal but there is no
improvement. The skin lesions that he had were non-
itchy, spreading from feet to upwards until both knees.
There was no personal or family history of atopy. There
was no history of food or drug allergy.
On examination, he was well and afebrile. His blood
pressure was 132/82 mmHg, and his pulse rate was 76
beats per minute. His lower limb examination showed
diffuse dry scaly mild erythematous macules
symmetrically involving mainly the dorsal aspect of both
legs. His blood investigations indicated normal findings.
For further management, he was referred to dermatology
department at general hospital. Dermatologist diagnosed
his conditions as skin eruption towards Valsartan.
Therefore, Valsartan was stopped, and the prescription of
Amlodipine was continued. Not later after that, his skin
lesion gradually improved, and the blood pressure was
well controlled upon the prescription of Bisoprolol.
Figure 1. Image of exanthematous macular skin lesions of
both legs.
DISCUSSION
Angiotensin II receptor blocker (ARB) is an
antihypertensive agent that specially design to block
angiotensin II receptors 1. It has cardioprotective and
renoprotective effects 1. Valsartan is one of the important
angiotensin II receptor blocker (ARB), indicated for the
treatment of hypertension 1.
Previous case reports described that Valsartan was
associated with various medical conditions and adverse
events including dizziness, headache, dry cough, acute
interstitial nephritis, hypoglycemic attack, malignant
melanoma and psychiatric symptoms 1,5-8. However, only
limited cases reported Valsartan related with cutaneous
side effects 2,3,4. There are a few studies reported the
cutaneous side effects of other ARBs such as Olmesartan,
Irbesartan and Losartan 4,9-12. Clinicians should be aware
of the cutaneous side effects of this commonly used agent.
CONCLUSIONS
Many antihypertensive drugs from beta blockers, calcium
channel blockers, diuretics and angiotensin-converting
enzyme inhibitors (ACE-I) groups have been linked to
adverse cutaneous effects 1. However, only limited cases
stated that ARB specifically Valsartan related with skin
manifestation side effects. Valsartan that commonly used
in treating hypertensive’s patient should be addressed as
one of the triggering factors for exanthematous skin
manifestation.
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